Eric Marandett on The Biologics Price Competition and Innovation Act

IPPro Life Sciences

 | September 9, 2015

 | Eric Marandett

Eric Marandett was quoted in "A Riddle Wrapped in a Mystery Inside an Enigma" in IPPro Life Sciences, where he discusses the BPCIA and Amgen's decision to challenge the approval of Sandoz's Zarxio.  He explains that although the Federal Circuit dismissed some of Amgen's claims, they did agree that Sandoz could not market Zarxio for 180 days, giving Amgen a six-month exclusivity period.  He also says that the Federal Circuit panel being so divided makes a rehearing of the case a possibility.  


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.